Drug Profile


Alternative Names: CI 1042; DI 1520; ONYX-015

Latest Information Update: 19 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onyx Pharmaceuticals
  • Developer Onyx Pharmaceuticals; Pfizer
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Barrett's oesophagus; Cancer; Cancer metastases; Colorectal cancer; Head and neck cancer; Liver cancer; Oropharyngeal dysplasia; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 23 Jun 2003 Discontinued - Phase-I for Barrett's oesophagus in USA (Intraluminal)
  • 23 Jun 2003 Discontinued - Phase-I for Ovarian cancer in United Kingdom (Intraperitoneal)
  • 23 Jun 2003 Discontinued - Phase-I for Ovarian cancer in USA (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top